rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Adial Pharmaceuticals, Inc

ADIL · Nasdaq

Health CareBiotechnologyJust started moving

ADIL stood above a rising 150-day average in 6 of the last 52 weekly readings, including each of the last 6 weeks. It is 16.5% above that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Just started moving
Weeks in an uptrend
6 in a row
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$213K
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
18 (+3)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 6 of 52 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$125KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months5
Sale orders, 12 months0
Buyers · sellers1 · 0
WhoDidSharesTraded
Coastlands Capital Lp10% ownerbought1,233at $2.7516 Jul 2026filed 16 Jul 2026
Coastlands Capital Lp10% ownerbought2,000at $2.6514 Jul 2026filed 16 Jul 2026
Coastlands Capital Lp10% ownerbought1,700at $2.7010 Jul 2026filed 13 Jul 2026
Coastlands Capital Lp10% ownerbought10,053at $2.799 Jul 2026filed 13 Jul 2026
Coastlands Capital Lp10% ownerbought25,000at $2.6029 Jun 2026filed 1 Jul 2026
Wendy B. YoungDirectorbought36,378at $2.7512 Jun 2026filed 16 Jun 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders18+3 on the quarter
New · exited5 · 2
Reported value$1.9M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Stonepine Capital Management, LLCnew · filed 14 Aug 2026727,563$1.6M+727,563
JANE STREET GROUP, LLCnew · filed 14 Aug 202632,119$82K+32,119
CITADEL ADVISORS LLCnew · filed 14 Aug 202629,547$76K+29,547
StoneX Group Inc.new · filed 12 Aug 202619,699$36K+19,699
UBS Group AGadded · filed 13 Aug 202619,147$49K+18,605+3432.7%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 202612,393$32K-11,856−48.9%
China Universal Asset Management Co., Ltd.new · filed 24 Jul 20268,000$20K+8,000
VANGUARD FIDUCIARY TRUST COunchanged · filed 13 Aug 20265,879$15K00.0%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20265,831$15K+5,470+1515.2%
Manchester Capital Management LLCunchanged · filed 13 Aug 20261,923$4,92300.0%
31 Mar 2023 – 30 Jun 2026
21221Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Wendy B. Young Company insiderDirector · last 17 Sep 20260 · 0
Coastlands Capital LP Company insider10% owner · last 16 Jul 20265 · 0
Matt Davidson Company insiderChief Development Officer · last 12 Jun 20260 · 0
Cary J. Claiborne Company insiderChief Executive Officer · last 7 Apr 20260 · 0
J. Kermit Anderson Company insiderDirector · last 7 Apr 20260 · 0
Kevin Schuyler Company insiderDirector · last 7 Apr 20263 · 0
Robertson H. Gilliland Company insiderDirector · last 7 Apr 20261 · 0
Tony Goodman Company insiderChief Operating Officer · last 7 Apr 20261 · 0
Vinay Shah Company insiderChief Financial Officer · last 7 Apr 20260 · 0
James W. Newman, Jr. Company insiderDirector · last 29 May 20254 · 0
Joseph Truluck Company insiderChief Financial Officer · last 25 Mar 20240 · 0
Bankole A. Johnson Company insiderDirector · last 23 May 20232 · 4

Same industry

MRNA ModernaLeading+154%
ENTX Entera BioLeading+49%
XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-148%
Share count trendFY 2025 · to 4 Mar 202628.5%
Cash and equivalentsFY 2025 · to 31 Dec 2025$5.9M

Analyst forecasts

No analyst forecasts yet.